Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 May;71(5):3961–3971. doi: 10.1128/jvi.71.5.3961-3971.1997

Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard.

B Poon 1, J B Jowett 1, S A Stewart 1, R W Armstrong 1, G M Rishton 1, I S Chen 1
PMCID: PMC191548  PMID: 9094673

Abstract

The product of the human immunodeficiency virus type 1 (HIV-1) vpr gene induces cell cycle arrest in the G2 phase of the cell cycle and is characterized by an accumulation of the hyperphosphorylated form of cdc2 kinase. This phenotype is similar to the effect of DNA-damaging agents, which can also cause cells to arrest at G2. We previously reported that Vpr mimicked some of the effects of a DNA alkylating agent known as nitrogen mustard (HN2). Here we extend these earlier observations by further comparing the activation state of cdc2 kinase, the kinetics of G2 arrest, and the ability to reverse the arrest with chemical compounds known as methylxanthines. Infection of cells synchronized in the G1 phase of the cell cycle with a pseudotyped HIV-1 resulted in arrest at G2 within 12 h postinfection, before the first mitosis. Similar to that induced by HN2, Vpr-induced arrest led to a decrease in cdc2 kinase activity. Vpr-mediated G2 arrest was alleviated by methylxanthines at concentrations similar to those needed to reverse the G2 arrest induced by HN2, and cells proceeded apparently normally through at least one complete cell cycle. These results are consistent with the hypothesis that Vpr induces G2 arrest through pathways that are similar to those utilized by DNA-damaging agents.

Full Text

The Full Text of this article is available as a PDF (779.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aviado D. M., Dettelbach H. R. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 1984 Jul;35(7):407–417. doi: 10.1177/000331978403500703. [DOI] [PubMed] [Google Scholar]
  2. Balliet J. W., Kolson D. L., Eiger G., Kim F. M., McGann K. A., Srinivasan A., Collman R. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology. 1994 May 1;200(2):623–631. doi: 10.1006/viro.1994.1225. [DOI] [PubMed] [Google Scholar]
  3. Bartz S. R., Rogel M. E., Emerman M. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol. 1996 Apr;70(4):2324–2331. doi: 10.1128/jvi.70.4.2324-2331.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bouhamdan M., Benichou S., Rey F., Navarro J. M., Agostini I., Spire B., Camonis J., Slupphaug G., Vigne R., Benarous R. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol. 1996 Feb;70(2):697–704. doi: 10.1128/jvi.70.2.697-704.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen E. A., Terwilliger E. F., Jalinoos Y., Proulx J., Sodroski J. G., Haseltine W. A. Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr. 1990;3(1):11–18. [PubMed] [Google Scholar]
  6. Collins J. M., Berry D. E., Cobbs C. S. Structure of parental deoxyribonucleic acid of synchronized HeLa cells. Biochemistry. 1977 Dec 13;16(25):5438–5444. doi: 10.1021/bi00644a006. [DOI] [PubMed] [Google Scholar]
  7. Connor R. I., Chen B. K., Choe S., Landau N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995 Feb 1;206(2):935–944. doi: 10.1006/viro.1995.1016. [DOI] [PubMed] [Google Scholar]
  8. Dezube B. J., Pardee A. B., Chapman B., Beckett L. A., Korvick J. A., Novick W. J., Chiurco J., Kasdan P., Ahlers C. M., Ecto L. T. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1993 Jul;6(7):787–794. [PubMed] [Google Scholar]
  9. Dezube B. J. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis. 1994 Mar;18(3):285–287. doi: 10.1093/clinids/18.3.285. [DOI] [PubMed] [Google Scholar]
  10. Draetta G., Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell. 1988 Jul 1;54(1):17–26. doi: 10.1016/0092-8674(88)90175-4. [DOI] [PubMed] [Google Scholar]
  11. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology. 1994 May;45(5):339–345. doi: 10.1177/000331979404500502. [DOI] [PubMed] [Google Scholar]
  12. Fingert H. J., Chang J. D., Pardee A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res. 1986 May;46(5):2463–2467. [PubMed] [Google Scholar]
  13. Fingert H. J., Pu A. T., Chen Z. Y., Googe P. B., Alley M. C., Pardee A. B. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res. 1988 Aug 1;48(15):4375–4381. [PubMed] [Google Scholar]
  14. Fletcher T. M., 3rd, Brichacek B., Sharova N., Newman M. A., Stivahtis G., Sharp P. M., Emerman M., Hahn B. H., Stevenson M. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J. 1996 Nov 15;15(22):6155–6165. [PMC free article] [PubMed] [Google Scholar]
  15. Gibbs J. S., Lackner A. A., Lang S. M., Simon M. A., Sehgal P. K., Daniel M. D., Desrosiers R. C. Progression to AIDS in the absence of a gene for vpr or vpx. J Virol. 1995 Apr;69(4):2378–2383. doi: 10.1128/jvi.69.4.2378-2383.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hattori N., Michaels F., Fargnoli K., Marcon L., Gallo R. C., Franchini G. The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. Proc Natl Acad Sci U S A. 1990 Oct;87(20):8080–8084. doi: 10.1073/pnas.87.20.8080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. He J., Choe S., Walker R., Di Marzio P., Morgan D. O., Landau N. R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol. 1995 Nov;69(11):6705–6711. doi: 10.1128/jvi.69.11.6705-6711.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Heinzinger N. K., Bukrinsky M. I., Haggerty S. A., Ragland A. M., Kewalramani V., Lee M. A., Gendelman H. E., Ratner L., Stevenson M., Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7311–7315. doi: 10.1073/pnas.91.15.7311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hoch J., Lang S. M., Weeger M., Stahl-Hennig C., Coulibaly C., Dittmer U., Hunsmann G., Fuchs D., Müller J., Sopper S. vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol. 1995 Aug;69(8):4807–4813. doi: 10.1128/jvi.69.8.4807-4813.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jowett J. B., Planelles V., Poon B., Shah N. P., Chen M. L., Chen I. S. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol. 1995 Oct;69(10):6304–6313. doi: 10.1128/jvi.69.10.6304-6313.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kondo E., Mammano F., Cohen E. A., Göttlinger H. G. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol. 1995 May;69(5):2759–2764. doi: 10.1128/jvi.69.5.2759-2764.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lang S. M., Weeger M., Stahl-Hennig C., Coulibaly C., Hunsmann G., Müller J., Müller-Hermelink H., Fuchs D., Wachter H., Daniel M. M. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol. 1993 Feb;67(2):902–912. doi: 10.1128/jvi.67.2.902-912.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lau C. C., Pardee A. B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci U S A. 1982 May;79(9):2942–2946. doi: 10.1073/pnas.79.9.2942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Maity A., McKenna W. G., Muschel R. J. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 1994 Apr;31(1):1–13. doi: 10.1016/0167-8140(94)90408-1. [DOI] [PubMed] [Google Scholar]
  25. Murnane J. P., Byfield J. E., Ward J. F., Calabro-Jones P. Effects of methylated xanthines on mammalian cells treated with bifunctional alkylating agents. Nature. 1980 May 29;285(5763):326–329. doi: 10.1038/285326a0. [DOI] [PubMed] [Google Scholar]
  26. Murnane J. P. Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. Cancer Metastasis Rev. 1995 Mar;14(1):17–29. doi: 10.1007/BF00690208. [DOI] [PubMed] [Google Scholar]
  27. Murray A. W. Creative blocks: cell-cycle checkpoints and feedback controls. Nature. 1992 Oct 15;359(6396):599–604. doi: 10.1038/359599a0. [DOI] [PubMed] [Google Scholar]
  28. Norbury C., Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61:441–470. doi: 10.1146/annurev.bi.61.070192.002301. [DOI] [PubMed] [Google Scholar]
  29. O'Connor P. M., Ferris D. K., Pagano M., Draetta G., Pines J., Hunter T., Longo D. L., Kohn K. W. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298–8308. [PubMed] [Google Scholar]
  30. O'Connor P. M., Ferris D. K., White G. A., Pines J., Hunter T., Longo D. L., Kohn K. W. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ. 1992 Jan;3(1):43–52. [PubMed] [Google Scholar]
  31. Paxton W., Connor R. I., Landau N. R. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol. 1993 Dec;67(12):7229–7237. doi: 10.1128/jvi.67.12.7229-7237.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Planelles V., Bachelerie F., Jowett J. B., Haislip A., Xie Y., Banooni P., Masuda T., Chen I. S. Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol. 1995 Sep;69(9):5883–5889. doi: 10.1128/jvi.69.9.5883-5889.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Planelles V., Jowett J. B., Li Q. X., Xie Y., Hahn B., Chen I. S. Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol. 1996 Apr;70(4):2516–2524. doi: 10.1128/jvi.70.4.2516-2524.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Re F., Braaten D., Franke E. K., Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol. 1995 Nov;69(11):6859–6864. doi: 10.1128/jvi.69.11.6859-6864.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rogel M. E., Wu L. I., Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol. 1995 Feb;69(2):882–888. doi: 10.1128/jvi.69.2.882-888.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Schmid I., Uittenbogaart C. H., Giorgi J. V. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry. 1991;12(3):279–285. doi: 10.1002/cyto.990120312. [DOI] [PubMed] [Google Scholar]
  37. Sharp P. M., Bailes E., Stevenson M., Emerman M., Hahn B. H. Gene acquisition in HIV and SIV. Nature. 1996 Oct 17;383(6601):586–587. doi: 10.1038/383586a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sheldrick K. S., Carr A. M. Feedback controls and G2 checkpoints: fission yeast as a model system. Bioessays. 1993 Dec;15(12):775–782. doi: 10.1002/bies.950151202. [DOI] [PubMed] [Google Scholar]
  39. Slupphaug G., Olsen L. C., Helland D., Aasland R., Krokan H. E. Cell cycle regulation and in vitro hybrid arrest analysis of the major human uracil-DNA glycosylase. Nucleic Acids Res. 1991 Oct 11;19(19):5131–5137. doi: 10.1093/nar/19.19.5131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Solomon M. J. Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol. 1993 Apr;5(2):180–186. doi: 10.1016/0955-0674(93)90100-5. [DOI] [PubMed] [Google Scholar]
  41. Teicher B. A., Holden S. A., Herman T. S., Epelbaum R., Pardee A. B., Dezube B. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res. 1991 Jul-Aug;11(4):1555–1560. [PubMed] [Google Scholar]
  42. Tristem M., Marshall C., Karpas A., Hill F. Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J. 1992 Sep;11(9):3405–3412. doi: 10.1002/j.1460-2075.1992.tb05419.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Vilpo J. A., Vilpo L. M. Normal uracil-DNA glycosylase activity in Bloom's syndrome cells. Mutat Res. 1989 Jan;210(1):59–62. doi: 10.1016/0027-5107(89)90044-4. [DOI] [PubMed] [Google Scholar]
  44. Westervelt P., Henkel T., Trowbridge D. B., Orenstein J., Heuser J., Gendelman H. E., Ratner L. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol. 1992 Jun;66(6):3925–3931. doi: 10.1128/jvi.66.6.3925-3931.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zhao Y., Cao J., O'Gorman M. R., Yu M., Yogev R. Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J Virol. 1996 Sep;70(9):5821–5826. doi: 10.1128/jvi.70.9.5821-5826.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES